Clinical Trial Update: An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Open-label extension study assessing safety and efficacy of upadacitinib (ABT-494) in adults with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2022-07-12